Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Zura Bio Q3 2026 Results: Net Loss of $25.8M, Loss Widens

Zura Bio Limited reported a net loss of $76.4 million for the nine months ended September 30, 2026, driven by increased research and development expenses. The company strengthened its balance sheet during the period, ending with $187.7 million in cash and cash equivalents compared to $109.4 million at the end of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-27.0-18.0
Net income-25.8-18.0
EPS (diluted, $ a share)$-0.20$-0.21

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ZURA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Zura Bio Ltd: key numbers

Share price
$1.08Close, Nov 16
Market cap
$104M
Shares outstanding
96.33MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Zura Bio Ltd

All →
7:07 AM ET 8-K
Clinical Trial Data

Zura Bio Clinical Trial Data

Zura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS) failed to meet its primary endpoint of percentage change from baseline in total abscess and inflammatory nodule count at Week 16. Key secondary endpoints were also not met, leading the company to discontinue development of the drug for the HS indication. Zura will continue its ongoing trials for tibulizumab in systemic sclerosis and polymyalgia rheumatica.

7:41 AM ET 8-K
Financial Results

Zura Bio Financial Results

Zura Bio reported third quarter 2026 financial results, highlighting a cash position of $187.7 million which is expected to fund operations through 2028. The company remains on track for topline Phase 2 data readouts for tibulizumab in hidradenitis suppurativa (Q4 2026) and systemic sclerosis (H1 2027).

“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027.”

Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer

“We continue to believe deeply in tibulizumab’s potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab’s unique potential.”

Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.